Effect of Motivational Therapy on Schizophrenia With Cannabis Misuse

NCT00798109 | Completed

• 2 other identifiers: P 070156AOM 07007
• Study Type: interventional
• Target: 97
• Locations: 1 country
• Sites: 1

Brief Summary

Schizophrenia is a severe mental illness with a lifetime morbidity risk close to 1 %, involving both genetic and environmental risk factors. Prospective studies have shown that heavy use of cannabis in adolescence moderately increases the risk of developing schizophrenia. Many data have also suggested that the co-occurrence of cannabis abuse in patients with schizophrenia has a deleterious impact on the clinical outcome of schizophrenia. Cannabis abuse by schizophrenic patients is a significant public health problem for which there is no empirically validated treatment. We are presently studying the efficiency of motivational therapy on cannabis consumption in patients with schizophrenia.

Conditions

Schizophrenia; Cannabis Dependence, Continuous

Keywords

Schizophrenia; Cannabis misuse comorbidity; Motivational interview; Randomised open trial

Outcome Measures

Primary Outcomes (1)

• Cannabis consumption evaluated by the Time-Line Follow Back at 6 months with mean percentage of abstinent day

  inclusion, 3 month, 6 month, 12 month

Secondary Outcomes (1)

• PANSS, GAF, number of DSM-IV criteria of cannabis dependence, May scale for treatment response, SF-12, la URICA, number of hospitalisation, mean number of joints per week, D9THC urinanalysis at 6M and cannabis consumption evaluated by the TLFB at 6M

  inclusion, 3 month, 6 month, 12 month. Only inclusion and 6 month for urianalysis

Study Arms (2)

Motivational Therapy

EXPERIMENTAL

Four motivational interview for cannabis abuse in schizophrenia population during one month

Behavioral: Motivational therapy

Usual Care

OTHER

Usual care with intensive psychotherapy

Behavioral: Usual care

Interventions

Motivational therapy BEHAVIORAL

One hour of motivational therapy each weak during 4 weeks

Motivational Therapy

Usual care BEHAVIORAL

Patients received at least six hour of usual therapy, as in the experimental group

Usual Care

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Schizophrenia or schizo-affective disorder according to DSM-IV criteria
• Meeting DSM-IV criteria for actual cannabis abuse or dependance
• in current and regular contact with mental health service
• with an age at interview of 18 years or more
• No evidence of organic brain disease or clinically significant concurrent medical illness or learning disability
• Written informed consent was obtained from all subjects (patients and parents).

You may not qualify if:

• Not membership to a regime of social security or to a CMU

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead

Study Sites (1)

Service de psychiatrie (Pr Adès)

Colombes, 92700, France

Location

MeSH Terms

Conditions

Schizophrenia; Marijuana Abuse

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders; Substance-Related Disorders; Chemically-Induced Disorders

Study Officials

• Caroline DUBERTRET, MD,PhD

  Assistance Publique - Hôpitaux de Paris

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 30, 2008
• First Posted: November 25, 2008
• Study Start: November 1, 2008
• Primary Completion: October 1, 2012
• Study Completion: April 1, 2013
• Last Updated: June 16, 2014

Record last verified: 2014-06

Locations

FR (1)